Targeting kidney scarring in older adults with chronic kidney disease using CAR-T cell therapy
Official title: Directly targeting renal fibrosis in the aged with CKD using in vivo CAR-T cell therapy
Funded at Indiana University Indianapolis · NIH-10951799 · Data updated 2026-11-12
This study is exploring a new way to help older adults with chronic kidney disease by using a special treatment called CAR-T cell therapy that targets kidney damage, with the hope of reducing inflammation and improving kidney function.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $431,771 |
| NIH project number | 1R21AG088701-01 |
| Project ID | NIH-10951799 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults aged 21 and above who are suffering from chronic kidney disease and experiencing kidney fibrosis.
✕Less likely to help
Patients with early-stage chronic kidney disease or those without significant fibrosis may not benefit from this research.
What this research studies
This research investigates a novel approach to treat chronic kidney disease (CKD) in older adults by using CAR-T cell therapy to directly target kidney fibrosis. The study aims to understand how this therapy can reduce inflammation and improve kidney function by modifying the immune response. Patients will receive CAR-T cells designed to specifically attack fibrotic tissue in the kidneys, potentially reversing damage caused by CKD. The research will involve clinical trials to assess the safety and effectiveness of this innovative treatment.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that significantly improves kidney function and quality of life for patients with chronic kidney disease.
How similar studies have gone: While CAR-T cell therapy has shown promise in treating certain cancers, its application in targeting kidney fibrosis is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: White, Kenneth E — Indiana University Indianapolis
- Study coordinator: White, Kenneth E
Related research
Other NIH-funded projects on the same topics.
-
Interface between immune cells and scarring in the eye
This grant looks at how immune cells influence scar formation in the cornea after injury and how this affects vision.
-
How often to treat schistosomiasis to protect the liver
A randomized trial will test different frequencies ofPraziquantel treatment to prevent liver damage in people aged 15–40 with schistosomiasis in Uganda.
-
Metabolic changes in cells that repair blood vessels in the eye lens to prevent scarring
A drug or approach that changes how certain cells that repair blood vessels in the eye work, to prevent scarring behind the retina in age-related macular degeneration patients treated with anti-VEGF therapy.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This project studies heart tissue changes in women with HIV in sub-Saharan Africa who are on antiretroviral therapy, to understand why they’re at higher risk for heart problems as they age.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This grant studies heart tissue changes in women living with HIV in sub-Saharan Africa to understand why heart failure risk is higher in this group.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.